Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 8/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15114599 | 1.00 | NR1H2 (0.37) | NR1H2CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL6542973 | 1.00 | NR1H2 (0.37) | NR1H2CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL15114607 | 1.00 | NR1H2 (0.37) | NR1H2CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL1397570 | 1.00 | NR1H2 (0.37) | NR1H2CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL16409167 | 0.88 | NR1H2 (0.34) | NR1H2CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL15116741 | 0.88 | NR1H2 (0.34) | NR1H2CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL20054314 | 0.88 | NR1H2 (0.34) | NR1H2CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL19388507 | 0.88 | NR1H2 (0.34) | NR1H2CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL15116546 | 0.88 | NR1H2 (0.34) | NR1H2CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL20221472 | 0.88 | NR1H2 (0.34) | NR1H2CHRM2CHRM1CHRM3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110248949-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2023-02-17 | — | — | CN | disclosed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| WO-2015005901-A1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | METAP2, METAP1, ENPEP | NR1H2 4500/4885CHRM2 1819/4885CHRM1 2640/4885 |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | NR1H2 2713/4885CHRM2 4882/4885CHRM1 4873/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | NR1H2 2713/4885CHRM2 4882/4885CHRM1 4873/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | NR1H2 2415/4885CHRM2 4881/4885CHRM1 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.